Pathways to care and outcomes among hospitalised HIV-seropositive persons with cryptococcal meningitis in South Africa. by Quan, Vanessa et al.
LSHTM Research Online
Quan, Vanessa; Toro-Silva, Sandra; Sriruttan, Charlotte; Chetty, Verushka; Chihota, Vio-
let; Candfield, Sophie; Vassall, Anna; Grant, Alison D; Govender, Nelesh P; for GERMS-SA;
(2019) Pathways to care and outcomes among hospitalised HIV-seropositive persons with cryp-
tococcal meningitis in South Africa. PloS one, 14 (12). e0225742. ISSN 1932-6203 DOI:
https://doi.org/10.1371/journal.pone.0225742
Downloaded from: http://researchonline.lshtm.ac.uk/id/eprint/4655633/
DOI: https://doi.org/10.1371/journal.pone.0225742
Usage Guidelines:
Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
https://researchonline.lshtm.ac.uk
RESEARCH ARTICLE
Pathways to care and outcomes among
hospitalised HIV-seropositive persons with
cryptococcal meningitis in South Africa
Vanessa QuanID1*, Sandra Toro-Silva2, Charlotte Sriruttan3,4, Verushka Chetty3,
Violet Chihota5,6, Sophie Candfield2,7, Anna Vassall2, Alison D. GrantID2,6,7,8, Nelesh
P. GovenderID3,4, for GERMS-SA¶
1 GERMS-SA, Division of Public Health Surveillance and Response, National Institute for Communicable
Diseases, a division of the National Health Laboratory Service, Johannesburg, South Africa, 2 TB Centre,
London School of Hygiene & Tropical Medicine, London, United Kingdom, 3 Centre for Healthcare-
Associated Infections, Antimicrobial Resistance and Mycoses, National Institute for Communicable Diseases,
a division of the National Health Laboratory Service, Johannesburg, South Africa, 4 School of Pathology,
Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 5 The Aurum
Institute, Johannesburg, South Africa, 6 School of Public Health, University of the Witwatersrand,
Johannesburg, South Africa, 7 The Mortimer Market Centre, Central and North West NHS Foundation Trust,
London, United Kingdom, 8 Africa Health Research Institute, School of Nursing and Public Health, University
of KwaZulu-Natal, Durban, South Africa
¶ GERMS-SA group is provided in the Acknowledgments.
* vanessaq@nicd.ac.za
Abstract
Introduction
Cryptococcus causes 15% of AIDS-related deaths and in South Africa, with its high HIV bur-
den, is the dominant cause of adult meningitis. Cryptococcal meningitis (CM) mortality is
high, partly because patients enter care with advanced HIV disease and because of failure
of integrated care following CM diagnosis. We evaluated pathways to hospital care, missed
opportunities for HIV testing and initiation of care.
Methods
We performed a cross-sectional study at five public-sector urban hospitals. We enrolled
adults admitted with a first or recurrent episode of cryptococcal meningitis. Study nurses
conducted interviews, supplemented by a prospective review of medical charts and labora-
tory records.
Results
From May to October 2015, 102 participants were enrolled; median age was 40 years (inter-
quartile range [IQR] 33.9–46.7) and 56 (55%) were male. In the six weeks prior to admis-
sion, 2/102 participants were asymptomatic, 72/100 participants sought care at a public-
sector facility, 16/100 paid for private health care. The median time from seeking care to
admission was 4 days (IQR, 0–27 days). Of 94 HIV-seropositive participants, only 62 (66%)
knew their status and 41/62 (66%) had ever taken antiretroviral treatment. Among 13
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participants with a known previous CM episode, none were taking fluconazole maintenance
therapy. In-hospital management was mostly amphotericin B; in-hospital mortality was high
(28/92, 30%). Sixty-four participants were discharged, 92% (59/64) on maintenance flucon-
azole, 4% (3/64) not on fluconazole and 3% (2/64) unknown. Twelve weeks post-discharge,
31/64 (48%) participants were lost to follow up. By 12 weeks post discharge 7/33 (21%) had
died. Interviewed patients were asked if they were still on fluconazole, 11% (2/18) were not.
Conclusions
Among hospitalised participants with CM, there were many missed opportunities for HIV
care and linkage to ART prior to admission. Universal reflex CrAg screening may prompt
earlier diagnosis of cryptococcal meningitis but there is a wider problem of timely linkage to
care for HIV-seropositive people.
Introduction
Cryptococcus causes 15% of AIDS-related deaths [1] and in South Africa, is the dominant
cause of adult meningitis [2]. Most cases of cryptococcal meningitis (CM) occur among per-
sons with advanced immunosuppression (i.e. CD4+ T-cell [CD4] count <200 cells/μl) [3].
CM-related mortality is high [1], ranging from 40% at two weeks among those treated with
optimal antifungal regimens and antiretroviral therapy (ART) [4] to 60% in routine care [5–7].
Continuing high CM incidence in many sub-Saharan African countries indicates a failure of
timely ART initiation prior to advanced HIV disease. High CM mortality is partly a conse-
quence of entering care with severe immunosuppression and advanced cryptococcal disease,
but also a failure of integrated care following CM diagnosis. In Cape Town, for instance, 73%
of patients admitted with CM had already received an HIV diagnosis a median of four months
earlier [8]. A study from Ghana in 2012–13 reported high in-hospital mortality (222/547,
40.6%) among HIV-seropositive adults with CM, 190 (85.6%) of whom were previously
known to be HIV-seropositive. A majority (141/222, 63.5%) of those who died were ART-
naive [9].
Hospital-based care of patients with CM puts substantial pressure on a health system. CM
is a frequent cause of hospitalisation in South Africa and Uganda [10, 11]. Routine reflex labo-
ratory cryptococcal antigen (CrAg) screening for HIV-positive persons with a CD4 count
<100 cells/μl (i.e. automatic CrAg testing of remnant settled plasma specimens) had been
implemented by the National Health Laboratory Service (NHLS) CD4 laboratories as a pilot
programme in two provinces from 2012 and expanded across South Africa in 2016 [12]. Apart
from improving case detection, management and outcomes associated with cryptococcosis,
this programme was also expected to partially shift CM diagnosis to primary care level. The
CrAg screening results were returned to the clinicians rather than to the microbiology labora-
tory, lumbar puncture was recommended for patients with a positive CrAg screen.
South Africa’s public healthcare system is tiered. Primary healthcare clinics are run by
nurses with infrequent to regular visits from consulting doctors. All such clinics have a desig-
nated referral hospital. During the scale-up of the national ART programme, the care of a large
proportion of HIV-seropositive individuals was shifted to nurses trained to initiate and con-
tinue ART at these clinics [13]. Nurses refer ill patients for hospital care. Lumbar punctures
are also not performed by nurses so any patient with symptoms of meningitis would be sent to
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a referral hospital [14]. Conversely, patients who are not too ill and seek initial care at a hospi-
tal can be sent to their nearest clinic to reduce the load on the hospital (hospital transport is
arranged). Acutely-ill patients who arrive at a hospital are seen. In our study, patients who
sought care directly at the hospital and were seen would have been acutely ill with CM and
admitted. Patients who sought care from a private doctor and who could not afford private
hospital care would have been referred to a public hospital for management. ART and mainte-
nance fluconazole medicines can be collected at the nearest clinic rather than the hospital at
which CM was diagnosed, but clinic stock-outs do occur. At the time of this study, patients
were not sent reminders to collect medication.
South Africa has implemented interventions for CM prevention, early diagnosis and
improved management. Amphotericin B deoxycholate has been available for routine CM
treatment since 2005, though prevention, monitoring and management of toxicities related to
this antifungal agent should be improved further [15]. A provider-initiated CrAg screening
pilot was established in the Western Cape Province in 2012 [16] and a reflex laboratory CrAg
screening pilot was implemented in Gauteng Province, Free State Province and KwaZulu-
Natal Province between 2012 and 2016. National CrAg screening was implemented in October
2016 [17]. With evidence from the ACTA trial [4] and recommendations by WHO that 5-FC
be included in a CM treatment regimen, a 5FC clinical access programme for CM started in
2018; 5-FC is still not registered in SA [17]. ART is now universally recommended in SA [18]
and the HIV test and treat initiative has the potential to decrease the number of patients seek-
ing care very late with CM.
The aim of this study was to evaluate pathways prior to hospital care, missed opportunities
to link to care or access ART and post-discharge outcomes among patients hospitalised with
cryptococcosis during an early phase of CrAg screening in South Africa.
Methods
We performed this cross-sectional study nested within a laboratory-based surveillance pro-
gramme (GERMS-SA) for cryptococcosis. The study was conducted at five public-sector
urban hospitals in South Africa’s Gauteng province from May to October 2015, before national
roll-out of reflex laboratory CrAg screening. Three hospitals were selected from districts where
reflex CrAg screening occured. Two hospitals were located in a district where reflex screening
had not yet been implemented. At the time of our study, patients were only eligible for ART
with a CD4 count�500 cells/μl [19].
As part of the GERMS-SA surveillance programme, surveillance nurses visited the hospital
microbiology laboratory daily to check for positive cryptococcal test results. They were not
involved in the reflex CrAg screening programme. An episode of cryptococcosis was defined
by a positive cerebrospinal fluid (CSF) India ink test, a positive CSF or blood CrAg test or cul-
ture of Cryptococcus neoformans or Cryptococcus gattii from any specimen. We assumed an
episode was recurrent if we found a record of a prior laboratory-confirmed episode or prior
antifungal treatment for CM within 30 days. For this nested study, participants were eligible
for enrolment if they were�18 years old, admitted to the study hospitals with a first or recur-
rent episode of laboratory-confirmed or presumed CM (e.g. symptoms of meningitis plus a
positive blood CrAg test and on amphotericin B) and provided informed consent. Persons
with CM who were identified after their admission through routine surveillance audits of the
NHLS laboratory information system (LIS), referred to as “audit cases”, were not available for
interview and were therefore excluded. For potential participants with a decreased level of con-
sciousness, surveillance nurses visited the patient during their hospital stay to check for an
improvement; if no improvement occurred, or if the potential participant died in hospital,
Care pathways and outcomes in cryptococcal meningitis
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their next of kin was approached and offered participation in the study. Written informed con-
sent was obtained from the participant or the next of kin after an explanation by the study
nurse. Interviews were conducted by surveillance nurses in the preferred language of the par-
ticipant or next of kin. Information collected included demographic details, contacts made
with the health system during the course of the illness, processes which resulted in the current
hospital admission, barriers and facilitators to accessing health care, management of the epi-
sode of cryptococcosis in hospital and in-hospital outcomes. Interviews were supplemented by
a prospective review of medical and laboratory records. Approximately 12 weeks after hospital
discharge, participants or their next of kin were contacted telephonically to assess vital status.
The case report forms were piloted at a large academic hospital and relevant changes were
then made. Data were captured on the standardised case report form, checked for correctness
and captured in MS Excel. This dataset was merged with the GERMS-SA surveillance database
using participant identifiers so that routine surveillance information (which includes labora-
tory data and clinical information) and additional information from this study were available
for each participant. Stata version 14 (StataCorp Inc., College Station, Texas, USA) was used
for a descriptive epidemiological analysis. We used the Wilcoxon rank sum test to compare
medians and Fishers’ exact test to compare categorical variables.
Study approval was obtained from the research ethics committees of the University of the
Witwatersrand and the London School of Hygiene & Tropical Medicine.
Results
Participants
During the study period from May through to October 2015, 345 cases of cryptococcosis were
detected through surveillance; 218 cases detected through audit were excluded (participants
not interviewed through routine GERMS-SA surveillance and thus very limited information
was available) (Fig 1). Of 127 patients who were identified prospectively as eligible for screen-
ing, 102 participants were enrolled. There were no differences in age or sex between cases
detected between those participants who were enrolled and those not enrolled (Table 1).
All 127 participants had a diagnosis of CM (either CSF-confirmed CM or a positive blood
specimen plus clinical signs of CM). Of 102 enrolled, 89 were first episodes and 13 recurrent
and of 25 not enrolled, 21 were first episodes and four recurrent. None of the recurrent cases
had a CSF CrAg test as the only positive test. Among the 102 enrolled participants, informa-
tion was captured by participant interview in 70% (n = 71) and the remainder by next of kin
interview. Eighty-five (83%) participants were from hospitals where CrAg screening was not
operational and 17 from sites with routine CrAg screening. Of the 102 participants, only one
had a screening blood CrAg test�14 days before her CM diagnosis, which may have prompted
earlier CM diagnosis and treatment.
Health-care seeking behaviour six weeks prior to admission
Public clinic information. Of the 102 participants, 100 had symptoms in the six weeks
prior to their admission. The majority (72/100; 72%) first sought healthcare for symptoms at a
public-sector clinic or hospital where a minimal or no fee is levied. A large number of visits
were made to various health care providers before participants were admitted but mostly at
public clinics (median 1; range 1–7 visits) (Table 2).
Of 38 participants who did not first attend a primary healthcare clinic in the public sector
and who answered the question, “what reasons best describe why you did not visit a public for
your symptoms?”: 17/38 (45%) went directly to hospital because they were so ill, 10/38 (26%)
preferred to look for help elsewhere, 5/38 (13%) were unsure that they needed to get help and
Care pathways and outcomes in cryptococcal meningitis
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6/38 (16%) provided no reason or other reasons (e.g. did not know where the nearest clinic
was, was concerned about the long clinic wait, was afraid that they would be admitted to hospi-
tal). Of 57 who visited a public clinic, 43 (75%) visited only one clinic and 48 (84%) visited the
clinic closest to them; the nine who attended a clinic further from home had the following rea-
sons: they were treated better (n = 2), they wanted privacy (n = 2), the participant was turned
away from closest clinic (n = 1), there was a shortage of treatment at the nearer clinic (n = 1)
and the participant was referred from work (n = 1).
Other health care providers. Of 100 participants, 16 paid for healthcare (at a private doc-
tor or traditional healer) and 12 went to a pharmacy or supermarket to buy medicines
(Table 2). No participants sought care at a private hospital casualty department. The median
Fig 1. Screening and enrolment of participants.
https://doi.org/10.1371/journal.pone.0225742.g001
Table 1. Characteristics of cases detected through surveillance audit, enrolled participants and those who were not enrolled.
Characteristic Enrolled (n = 102) Not enrolled (n = 25) p-value# Audit cases (n = 218)
Median age in years, (IQR) 39.9 (33.9–46.7) 40.4 (31.6–44.9) 0.69 38.8 (32.8–45.2) (n = 172)
Male sex, n/N (%) 56/102 (55) 19/25 (76) 0.06 112/202 (55)
Specimen type, n/N (%) 0.14 Not available
CSF 87/102 (85) 25/25 (100)
Serum/ plasma 8/102 (8) 0/25 (0)
Blood culture 7/102 (7) 0/25 (0)
Cryptococcal antigen test positive, n/N (%) 90/99 (91)� 19/25 (76)�� 0.06 Not available
Cryptococcal culture positive, n/N (%) 78/85 (92)��� 12/14 (86)��� 0.61 Not available
CSF India ink positive, n/N (%) 76/77 (99)�� 24/24 (100)��� 0.80 Not available
# p-value was comparison of those enrolled vs not enrolled
�3 had no result,
��6 had no result,
��� rest had no data
https://doi.org/10.1371/journal.pone.0225742.t001
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time from first seeking care to admission was four days (IQR, 0–27 days) among 99 partici-
pants with data.
HIV testing and missed opportunities
Of 102 participants, 94 were HIV-seropositive, two were HIV-seronegative and six had an
unknown HIV status (four were next of kin interviews, the other two patients did not have an
HIV result). On interview, 78/94 (83%) knew that they or their relative had been tested for
HIV, 11 said they had never been tested (two were tested on this admission, one of whom had
been previously treated for pulmonary TB) and for five, this information was unknown (all
next of kin interviews). Of the 78 who knew they were tested, 62 (79%) said that they or their
relative was HIV-seropositive, six said they were HIV-seronegative and 10 did not know (Fig 2
–missed opportunities for HIV testing at any health-care contact are highlighted in yellow
boxes).
The date of “first HIV test” recorded was available for 67 patients. The time from when they
were first tested for HIV to this admission for CM ranged from 0 days to 20 years (median 271
days, IQR 76 days to 40 months). There were 41 participants who tested at a public clinic, 36
knew whether a CD4 count had been done: seven said they had no CD4 count done and 29
(80%) said they had a CD4 count performed but only 17 (58%) returned for their result. Rea-
sons provided for not returning for their CD4 count results (n = 10) included: three felt too ill
to come back, two relocated, two did not trust the result, two did not know to return, one
could not wait for the result.
At the time of the hospital diagnosis of cryptococcosis, there were 59 participants with a
CD4 count ranging from 1–234 cells/μl (median 34, IQR 18–75); only three had a CD4 count
>200 cells/μl; five of those participants knew their CD4 count six months prior to their diag-
nosis of cryptococcosis.
ART and linkage to care
Fig 2 also shows that of 62 participants who knew they were HIV-seropositive, 41 reported
ART use (one had stopped because the medicines made him/her feel ill but the other 40 were
currently on ART). Thirty-six knew the approximate date they had started ART and this ran-
ged from seven days to 110 months (median 218 days). Twenty participants had never been on
ART: eight had been told they required it but did not start (three did not complete adherence
Table 2. Participants’ health-seeking behaviour and visits to health-care facilities in the six weeks preceding admission.
Healthcare
facility
First place sought care for symptoms within
6 weeks of admission� (n = 100) n (%)
Attended for
any care
n (%)��
Total number of visits for any care
in 6 weeks prior to admission
Range and median number of visits for
any care in 6 weeks prior to admission
Public clinic 50 (50) 57 (57) 84 1–7; 1
Public hospital 22 (22) 30 (30) 34 1–3; 1
Private doctor 14 (14) 19 (19) 23 1–3; 1
Pharmacy 8 (8) 35 (35) 55 1–5; 1
Traditional healer 2 (2) 8 (8) 12 1–3; 1
Supermarket 4 (4) N/A N/A N/A
Private hospital
casualty
0 0 0 N/A
�2 patients had no symptoms and did not seek care but still had laboratory-confirmed meningitis
�� more than one place where care was sought
https://doi.org/10.1371/journal.pone.0225742.t002
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counselling, two were afraid of side effects and one each relocated, reported having no food,
and being on other treatment); four reported they had not been told they needed ART and one
was not eligible because of a high CD4 count. Thirty-two participants had recorded dates for
“first HIV test” and ART initiation. The interval between HIV testing and starting ART ranged
from 0–4202 days (11.5 years) (median 31 days, IQR 0–266 days).
Post-discharge follow-up of prior episodes of cryptococcosis and other
missed opportunities
Thirteen of eighty-seven reported a previous episode of CM (number of episodes ranged from
one to five [median 1, IQR 1–2]) and 11 of these knew they had received treatment for menin-
gitis (corroborated with documentation from previous medical records). Nine of 11 partici-
pants reported receiving fluconazole on prior discharge (two never received) for a period
ranging from one week to 30 weeks (median 4 weeks, IQR 2–6 weeks). All nine stopped their
fluconazole for one of the following reasons: a healthcare worker stopped treatment for three,
three did not know to continue after their initial course, three stopped on their own (two felt
better and one felt ill on fluconazole). Of those 13 participants with a recurrent CM episode,
information on ART was available for eight of them and five were on ART.
Management of cryptococcosis in hospital
We collected treatment information during the admission for CM for 81 patients, 75 (93%) of
whom received both amphotericin B (AmB) and fluconazole, five (6%) received AmB only
Fig 2. HIV testing, antiretroviral treatment and missed opportunities. Legend: NOK = next of kin, �Reasons for not
starting ART: afraid of side effects (n = 2), no food (n = 1), dropped out/ did not complete adherence counselling
(n = 3), relocated (n = 1), on some treatment (n = 1).
https://doi.org/10.1371/journal.pone.0225742.g002
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and one received fluconazole only (800 mg twice daily for 10 days). Of the 77 who were on flu-
conazole (with a known duration of treatment), treatment ranged from 1–45 days (median 16
days, IQR 10–18). Of 78 patients who received AmB with a known duration of treatment, this
ranged from 1–27 days (median 14 days, IQR 9–14 days).
Outcomes and management post-hospitalisation
From the information available, we determined in-hospital outcome for 92 participants: 64
(70%) recovered and 28 (30%) died in hospital. For 26 of 28 participants who died in hospital
(with date of death recorded), median time to death was 9.5 days (IQR 17.5 days, range 0–64
days). The only participant with CrAg screening done before diagnosis was a 40-year-old
woman who had a blood CrAg test on 26 June 2015, followed by transfer to an academic hospi-
tal on 4 July where she started fluconazole that day and AmB the following day. A lumbar
puncture (with an opening pressure of 40 cm CSF) was performed on 7 July confirming CM.
She received treatment until 14 July and was discharged on fluconazole; she died a month
later.
Sixty-four participants were discharged alive from hospital, 59 (92%) of whom were dis-
charged on fluconazole, three (4%) were not, two (4%) were unknown. Of the 64 participants
who were discharged alive, 31 (48%) were lost to follow up at 12 weeks. Thirty-three of 59
(56%) participants discharged on fluconazole had outcome data, among whom 7/33 (21%) had
died. Only participants who were interviewed were asked whether they were still taking flucon-
azole. Sixty-nine per cent (18/26) were interviewed: 2/18 (11%) had stopped the fluconazole;
reasons were not explored. (Fig 3). Assuming that all who were lost to follow up either survived
or died, the mortality ranged from 41% to 72% at 12 weeks.
Discussion
In this study of care pathways and outcomes in CM, we have described the difficulties that
very ill patients faced when navigating the complex South African healthcare system. Other
SSA countries face similar challenges with a large burden of HIV/AIDS diverting scarce
resources from competing health needs. Healthcare system strengthening in SSA is central to
improve delivery of care for HIV/AIDS, co-morbidities and other priority conditions. Obsta-
cles to adequate delivery of care must be pinpointed within a health care system before they
can be overcome [20–22]. The literature on patient pathways for CM is very sparse. In 2011,
Lessels et al described inadequate HIV status confirmation among patients seeking care for
CM and a high rate of loss to follow-up once discharged, highlighting poor linkage between
hospital services and PHC clinics providing ongoing HIV care and treatment in rural Kwa-
Zulu-Natal [6].
Prior to CM diagnosis, we identified numerous missed opportunities relating to HIV test-
ing, including participants who did not know their HIV status, those who said they had never
been tested and those who had been tested but thought they were HIV-seronegative. Reasons
for delays in HIV testing have been explored in prior studies: social stigma, a perception of low
HIV risk until they have physical symptoms, uncertainty about ART availability and side
effects remain issues to be dealt with [23–26].
Linkage to HIV care is a challenging component of the HIV care cascade. There were
missed opportunities related to pre-CM ART initiation, including lack of CD4 result follow
up, incomplete ART adherence counselling and ART interruption. National laboratory-based
cryptococcal disease surveillance data (GERMS-SA programme) in South Africa shows that
more than half of patients admitted with cryptococcosis are ART-experienced (53% in 2015,
57% in 2016 and 60% in 2017) [27–29]. Earlier HIV testing (including testing by pharmacists,
Care pathways and outcomes in cryptococcal meningitis
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traditional healers and self-testing) could facilitate earlier HIV diagnosis and referral for ART.
In a rural South African setting, home-based HIV-testing was well accepted although coverage
for men was lower, but linkage to care took up to a year to achieve [30]. Steele and colleagues
found that only 36% of those newly diagnosed after community-based HIV-testing in Kwa-
Zulu-Natal between 2013 and 2017 were linked to care within 6 months [31].
HIV self-testing (which has been included in the South African National Strategic Plan for
HIV, STIs and TB, 2017–2022 [18]) is a relatively new initiative which holds promise to
improve knowledge of HIV status [32–34], though advanced HIV disease will only be pre-
vented if people with positive test results link to effective ART.
Fig 3. Outcomes during admission, post discharge and failure of retention in care. Key: NOK = next of kin. �lost to follow up.
https://doi.org/10.1371/journal.pone.0225742.g003
Care pathways and outcomes in cryptococcal meningitis
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Retention in ART care has many challenges including navigation through the healthcare
system, individual perceptions and medication-related issues. Not all clinics are open 24
hours, waiting times may be very long and patients are concerned about loss of confidentiality.
Mental health and alcohol/ substance abuse have further been found to impact retention in
ART care [35, 36]. Strengthening follow up of patients at a community level, including the use
of mobile technology, may improve retention although these are costly and labour-intensive
approaches [26, 37, 38].
The national South African CrAg reflex laboratory screening programme has increased
detection of cryptococcosis. From October 2016 to September 2017, 276 125 patients with a
CD4 count <100 cells/μl were screened nationally (95% coverage) and 15 757 (5.7%) were
identified with cryptococcal antigenaemia. The effectiveness of the programme in terms of
mortality reduction is being evaluated through the NICD’s CAST-NET project [17]. In our
study (which was conducted during the early phase of reflex CrAg screening) only one patient
had a reflex CrAg test which may have led her to be diagnosed with CM earlier. She did, how-
ever, die which illustrates the complexity of the pathway to improved outcomes. This point is
reinforced by the finding that the median time between first seeking care and admission was
only four days suggesting that it may be hard to improve outcomes by intervening at this
point. What is really needed are further efforts to prevent advanced disease by earlier ART
initiation.
In-hospital management of CM included amphotericin B for the vast majority of partici-
pants. Despite this, the in-hospital mortality was high (30%). This may be related to use of less-
effective antifungal regimens in a resource-limited setting, complications associated with
healthcare-associated infections, toxicity of antifungal medicines and inadequate management
of raised intracranial pressure. A new WHO guideline for cryptococcal disease (March 2018)
includes a one-week short course of amphotericin B deoxycholate and 5-flucytosine followed
by one week of fluconazole [3]. This regimen reduces mortality by 38%, is safer and reduces
the risk of anaemia (a frequent complication of antifungal treatment) by 69%, when compared
to the standard two-week regimen. Most participants were appropriately discharged on con-
solidation/ maintenance doses of fluconazole, though there were a few missed opportunities
too.
Following discharge from hospital, patients reported difficulties with continuing antifungal
treatment and linking to ART at an appropriate time, particularly related to an inadequate
healthcare worker explanation of the need for long-term antifungal treatment for CM. Adher-
ence is a key challenge in long-term treatment and should be promoted by good counselling
and a caring environment before beginning ART and antifungal therapy. Of our study partici-
pants who were discharged on fluconazole and available for the 12-week follow up, two had
discontinued fluconazole, though reasons were not pursued. Continued counselling and edu-
cation throughout treatment, pill counts done at every visit, assisting with practical reminders,
helping to problem solve, understanding the challenges of long-term therapy, encouraging dis-
closure to a friend or family so there is support and regular support groups are all useful in
adherence. Improving health systems to avoid treatment stock outs, to make care more acces-
sible, possibly longer opening hours, reducing waiting times ease of collecting medication in
the community rather than only the clinic, are also necessary [26, 39]. Systems to reduce
patient loss-to-follow-up is key to managing long-term treatment as well as tracing patients
who are lost to follow-up and restarting them on care.
Information post discharge was scarce; however, among patients for whom there was data,
most were alive at 12 weeks. This is a biased estimate since “loss to follow-up” of HIV positive
patients usually includes many unreported deaths. Assuming all who were lost to follow up
died, mortality would have been 72% at 12 weeks. A study done in 2009, in a Johannesburg
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urban hospital, showed poor post-discharge linkage to care for TB/HIV and late presentation
at a primary clinic for follow up. Twenty three per cent (137/456) of patients failed to link to
TB care, 30% (138/456) who were linked arrived late (>1 week). Thirty eight per cent (186/
486) of patients with HIV-associated TB failed to link to HIV care, but 32% (96/300) who were
linked sought care more than 30 days late [40].
Strengths of this study include its uniqueness being nested within an ongoing, active sur-
veillance system. We enrolled 80% of potentially eligible participants and data were collected
by prospective interview. The use of next of kin interviews helped to increase representation of
the sickest patients in the data set. Limitations include missing data because of next of kin
interviews, patients not knowing enough about their health, incomplete medical records, and
incomplete recollection of dates of when the patient was ill or when he/she was on previous
treatment. The follow-up study did not reach all patients, only half who recovered were
contacted.
Conclusions
We have documented common problems in the pathway to care for patients with CM. We
documented many missed opportunities for HIV testing, ART initiation and linkage to post-
discharge HIV care. CrAg screening may improve CM case-finding and the availability of
5-flucytocine regimen may reduce CM mortality but the incidence of CM is only likely to
decrease substantially when more people know their HIV status and start ART earlier.
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